October 13, 2020 -- Axol Biosciences has added multielectrode array (MEA) screening services for human-induced pluripotent stem cell (hiPSC)-derived cells to its service offering for preclinical drug discovery.
The company said that its new MEA screening services optimize hiPSC-derived cell culture, while also providing electrophysiology acquisition and analysis from physiologically relevant human cell models.
The expansion combines Axol's hiPSC-derived human cells and electrophysiological experience with Axion Biosystems' Maestro Pro MEA platform, according to the firm. The Maestro Pro supports continuous label-free and real-time data acquisition and analysis from 768 electrodes in up to a 96 wp format, Axol said.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
